Abstract

Alzheimer’s disease (AD) is associated with memory impairment and altered peripheral metabolism. Mounting evidence indicates that abnormal signaling in a brain-periphery metabolic axis plays a role in AD pathophysiology. The activation of pro-inflammatory pathways in the brain, including the interleukin-6 (IL-6) pathway, comprises a potential point of convergence between memory dysfunction and metabolic alterations in AD that remains to be better explored. Using T2-weighted magnetic resonance imaging (MRI), we observed signs of probable inflammation in the hypothalamus and in the hippocampus of AD patients when compared to cognitively healthy control subjects. Pathological examination of post-mortem AD hypothalamus revealed the presence of hyperphosphorylated tau and tangle-like structures, as well as parenchymal and vascular amyloid deposits surrounded by astrocytes. T2 hyperintensities on MRI positively correlated with plasma IL-6, and both correlated inversely with cognitive performance and hypothalamic/hippocampal volumes in AD patients. Increased IL-6 and suppressor of cytokine signaling 3 (SOCS3) were observed in post-mortem AD brains. Moreover, activation of the IL-6 pathway was observed in the hypothalamus and hippocampus of AD mice. Neutralization of IL-6 and inhibition of the signal transducer and activator of transcription 3 (STAT3) signaling in the brains of AD mouse models alleviated memory impairment and peripheral glucose intolerance, and normalized plasma IL-6 levels. Collectively, these results point to IL-6 as a link between cognitive impairment and peripheral metabolic alterations in AD. Targeting pro-inflammatory IL-6 signaling may be a strategy to alleviate memory impairment and metabolic alterations in the disease.

Highlights

  • Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with the highest prevalence in older adults[1]

  • We found a significant increase in hypothalamus/putamen ratios in AD compared to control subjects (Fig. 1b)

  • It is plausible that the gliosis we observed in post-mortem AD hypothalamus may be linked to the inflammatory process revealed by imaging, as gliosis has been associated with increased T2-weighted signals in a number of studies[35,38,46,47]

Read more

Summary

Introduction

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with the highest prevalence in older adults[1]. AD is classically recognized as a disease that affects cognition, metabolic alterations have been described in patients and in animal models[2,3,4,5]. One possibility is that damage to the blood-brain barrier (BBB)[6,7] triggered by mediators and other signaling molecules released from peripheral tissues leads to brain inflammation in AD. In AD brains, reactive astrocytes are associated with the chronic release of a variety. Lyra e Silva et al Translational Psychiatry (2021)11:251 of pro-inflammatory and toxic mediators[8,9] that can elicit synaptic dysfunction[10,11,12], alterations in the hypothalamuspituitary-adrenal (HPA) axis[13], and BBB dysregulation[14]. The chronic combination of central and peripheral inflammation may promote cognitive decline, brain and peripheral metabolic alterations in AD2,10,11,15

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call